CytomX Therapeutics, Inc.
CTMX
$3.36
$0.010.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -79.65M | -59.14M | -17.37M | 28.02M | 47.98M |
| Total Depreciation and Amortization | 942.00K | 1.24M | 1.38M | 1.28M | 1.57M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.83M | 11.46M | 8.98M | 8.92M | 8.84M |
| Change in Net Operating Assets | -15.53M | -33.65M | -68.58M | -110.47M | -135.83M |
| Cash from Operations | -82.41M | -80.09M | -75.59M | -72.25M | -77.43M |
| Capital Expenditure | -74.00K | -101.00K | -220.00K | -99.00K | -245.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -200.73M | -283.02M | -59.52M | -30.09M | -12.22M |
| Cash from Investing | -200.80M | -283.12M | -59.74M | -30.19M | -12.46M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 246.04M | 339.08M | 110.45M | 96.05M | 95.80M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5.86M | 5.86M | -- | -- | -- |
| Cash from Financing | 251.89M | 344.93M | 110.45M | 96.05M | 95.80M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -31.32M | -18.28M | -24.89M | -6.39M | 5.91M |